IntronA

Selected form

Interferon Alfa-2b

Method of action: Anti-Inflammatory, Antiproliferative, Antitumour, Immunomodulating, Immunostimulants

Treatment option: Hepatitis, Hepatitis B, Hepatitis C, Malignant Melanoma, Carcinoid Syndrome, Leukemia, Lymphoma, Weight Loss, Cancer,Multiple Myeloma, Cancer,Plasma Cell Myeloma

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of IntronA

Property	Description
Active ingredient	Interferon Alfa-2b
Form	Injectable solution or powder for injection
Pharmacological class	Immunomodulator, Antiviral agent, Antineoplastic agent
Common use	Systemic support against viral threats and cell proliferation
Origin	Recombinant protein (Biologic drug)

IntronA: Identity, Type, and Unique Features

IntronA is the trade name for a prescription-only medicine whose active component is Interferon Alfa-2b, a specific type of human protein known as a cytokine. It is fundamentally classified as a biologic drug and a Biological Response Modifier (BRM) due to its influence on cellular processes and the immune system.

A key differentiating feature of IntronA is its non-pegylated form, which contrasts with other interferons designed for extended release. The medicine is supplied as a sterile, ready-to-use injectable solution or as a powder for injection that requires reconstitution, preparing it for parenteral administration. This liquid form is often utilized in adult patient groups requiring systemic support against pathologies characterized by cellular and viral proliferation.

Composition and Origin: Is Interferon Alfa-2b Recombinant?

The Interferon Alfa-2b found in IntronA is a recombinant protein, meaning it is produced outside the human body using advanced Recombinant DNA technology. This method ensures a highly purified, consistent supply of this single-component molecule.

The active component is an engineered copy of a cytokine protein naturally produced by human white blood cells. This origin confirms its unique identity as a biologic agent. This interferon class functions by inducing an antiviral state in cells, establishing the molecule's foundational physiological action.

General Purpose: Fundamental Benefit of this Cytokine

The fundamental benefit of IntronA is its ability to deliver crucial communication signals that support the body's defense mechanisms. It assists the body in managing threats by enhancing its inherent capacity for antiviral activity and applying an antiproliferative effect to curb uncontrolled cell growth. For instance, the general use involves providing systemic support to the host immune responses in challenging settings, enabling the body to better combat pathologies driven by excessive cell division or viral burden.

What side effects are possible with IntronA?

Possible Side Effects and Safety Information

IntronA (interferon alfa-2b) is a medication that may cause a range of side effects. Patients should be closely monitored by their healthcare provider throughout treatment, including periodic clinical and laboratory evaluations.

Common Side Effects

The most frequently reported side effects are often described as flu-like symptoms, which can be intense, especially early in treatment. These typically include:

Fever and chills
Fatigue and malaise (general discomfort)
Headache
Muscle and joint aches (myalgia/arthralgia)
Nausea, vomiting, and diarrhea
Loss of appetite and weight loss
Injection site reactions (e.g., pain, redness, inflammation)

Many of these symptoms often decrease in severity after the first few weeks of therapy.

Serious and Important Safety Information

IntronA may cause or aggravate serious, potentially life-threatening conditions. Immediate medical attention is required if any of the following occur:

Neuropsychiatric disorders: Severe depression, suicidal thoughts or attempts, or aggressive behavior. Mood or behavioral changes require immediate reporting to a doctor.
Blood disorders: Decreased production of blood cells (e.g., low white blood cells, platelets, or red blood cells), which can lead to increased risk of infection, bleeding, or anemia.
Autoimmune, Ischemic, and Infectious disorders: The drug may trigger or worsen conditions such as thyroiditis, or lead to heart problems (e.g., arrhythmia, chest pain) or severe infections.
Liver and Eye problems: Signs of liver dysfunction (e.g., jaundice, dark urine) or significant vision changes require prompt evaluation.

Contraindications

IntronA should generally not be used in patients with severe, uncontrolled conditions, including:

Severe uncontrolled thyroid disease or epilepsy/central nervous system issues.
Severe kidney or liver impairment (especially liver cirrhosis with symptoms).
Severe heart disease or specific immune system disorders.
Known hypersensitivity to interferon alfa-2b or its components.

Patients who develop severe adverse reactions or persistent intolerance despite dose adjustment may need to permanently discontinue treatment.

Overdose and Emergency Response

Overdose and When to Seek Help

The official regulatory information for Interferon Alfa-2b (IntronA) describes that overexposure manifestations are generally consistent with the effects seen at therapeutic doses, but at a significantly higher severity. Documented cases of single-dose exposure, including those up to ten times the recommended dose, are reported in the clinical literature.

Documented Overdose Manifestations and Severe Outcomes

Official labeling warns that overdosage may lead to life-threatening or fatal outcomes. Serious events reported in association with high doses or prolonged exposure include myocardial infarction (heart attack), renal failure, and hemorrhage. Severe hematological toxicities and prominent hepatic enzyme abnormalities are also documented clinical manifestations.

Required Emergency Actions

No specific antidote is known for Interferon Alfa-2b. Consequently, the mandated management for overexposure is entirely symptomatic and supportive treatment. The regulatory instruction requires that patients experiencing persistently severe or worsening signs or symptoms must be withdrawn from therapy and seek immediate medical attention. Close clinical and laboratory monitoring must be conducted following any suspected overexposure to assess for and manage the documented severe organ system effects. Toxic effects after oral ingestion are not expected due to the drug's poor absorption via that route.

Therapeutic Uses of IntronA

What IntronA Treats: Main Uses and Benefits

IntronA is commonly used in multiple key therapeutic areas and is relevant in clinical settings involving specific disease manifestations.

Addressing Chronic Viral Activity and Malignancies

IntronA is applied in situations involving certain distressing symptoms related to ongoing viral load in Chronic Hepatitis B and Chronic Hepatitis C, conditions presenting with systemic or localized discomfort that may intensify temporarily. The application is relevant when supportive symptom management is appropriate for virologic control, which may help support liver functional stability and contributes to easing the symptom load of chronic disease. The medication is also relevant for managing several malignancies, including Hairy Cell Leukemia, certain lymphomas, Carcinoid Tumor, and Malignant Melanoma.

Its primary therapeutic applications are used across domains where additional symptomatic support is needed. This use provides support that helps ease the overall symptom burden and may assist with maintaining functional stability during symptomatic periods.

Quick Fact: Relief for Systemic Symptom Burden

IntronA's application may assist with managing symptomatic manifestations related to hematological changes in cancers, which helps address symptom clusters that may become intense or disruptive (such as unexplained fevers or night sweats).

Eligibility and Restrictions for Use

Eligibility Map: Who can and cannot use IntronA — Official Regulatory Information

The eligibility profile for IntronA (Interferon Alfa-2b) is defined by official population rules established by regulatory authorities.

Eligibility Scope

Classification	Population/Condition
Populations for whom use is Allowed	Adults (18+ years) for most indications; Pediatric patients 1 year and older (Chronic Hepatitis B); Children 3 years and older (Chronic Hepatitis C in combination therapy).
Populations for whom use is Contraindicated	Patients with known hypersensitivity to the medicine; severe liver disease (decompensated cirrhosis) or Autoimmune Hepatitis; severe kidney disease; severe heart disease; uncontrolled thyroid disease; or severe pre-existing psychiatric disorders, including active depression or suicidal ideation.

Age-Related Eligibility Rules

Use is not established in infants younger than 1 year (Chronic Hepatitis B) or under 3 years (Chronic Hepatitis C). While no hard restriction exists for older adults, the label notes they may be more sensitive to the medicine's effects.

Condition-Specific and Reproductive Status Restrictions

Eligibility is restricted for patients with certain underlying conditions. The medicine is contraindicated in patients with uncontrolled Central Nervous System problems, and those with pre-existing autoimmune disorders may require restricted use. Regarding reproductive status, IntronA may cause fetal harm; therefore, its use is not recommended during pregnancy, and effective contraception is mandatory for female patients of reproductive potential. Breastfeeding is also generally not recommended during treatment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

IntronA (interferon alfa-2b) has documented interactions with several categories of medicinal products, primarily involving effects on metabolism and additive toxicities, which are highly significant in clinical practice.

Key Interacting Agents and Mechanisms

Category or Specific Product	Interaction Mechanism / Result	Regulatory Classification
Fezolinetant	Increased levels/effect due to CYP1A2 metabolism inhibition.	Contraindicated
Theophylline, Zidovudine	Increased levels by decreasing their metabolism; requires close monitoring.	Monitor Closely
Immunosuppressants	Additive immunosuppressive effects, increasing the risk of infection.	Caution/Avoid
Acalabrutinib, Lamivudine, Hydroxyurea	Increased toxicity through pharmacodynamic synergism; requires caution and monitoring. Hydroxyurea co-use is associated with cutaneous vasculitic toxicities.	Monitor Closely
Drugs Causing Hepatotoxicity/Myelosuppression	Additive risk of liver damage or severe cytopenias (low blood counts); requires avoidance or modification.	Avoid/Monitor Closely
Warfarin	Increased anticoagulant effects by an unspecified mechanism; requires monitoring of INR.	Monitor Closely

Interaction-Related Restrictions

Due to the potential for severe effects, Fezolinetant must not be taken with IntronA. The concurrent or sequential use of agents that are nephrotoxic or ototoxic (e.g., inhaled tobramycin) is generally advised to be avoided. Caution is necessary with agents that carry a risk of myelosuppression or hepatotoxicity as the combination may worsen these effects. Patients taking any medicine that suppresses the immune system should be managed with caution due to the risk of additive immunosuppression.

Mechanism of Action

IntronA, a recombinant interferon alfa-2b, functions primarily as an agonist by binding to specific Type I interferon receptors (IFNAR1/2) located on the surface of target cells. This extracellular interaction activates the intracellular JAK-STAT signaling pathway.

This cascade results in the nuclear translocation of activated STAT complexes, which then bind to Interferon-Stimulated Response Elements (ISREs) in the genome.

This binding induces the transcription and subsequent expression of numerous Interferon-Stimulated Genes (ISGs). The proteins encoded by these ISGs establish an antiviral state within the cell by promoting the degradation of viral mRNA and inhibiting viral protein synthesis and replication. Furthermore, IntronA exerts an immunomodulatory effect by upregulating the expression of MHC antigens and directly modulating the activity of T-cells and Natural Killer (NK) cells. The mechanism also includes the suppression of abnormal cell proliferation and the promotion of apoptosis via cell cycle arrest.

Dosage and Administration Information

Instruction Map: How to use IntronA — Official Administration Guidelines

The administration of IntronA (interferon alfa-2b) must be initiated by a healthcare professional experienced in managing the patient's specific condition. The required procedural steps, routes, and dosing are highly dependent on the disease being treated.

Administration Scope

Classification	Rule/Specification
Route of Administration	Subcutaneous (SC) or Intramuscular (IM) injection are common routes. Intravenous (IV) infusion (e.g., for induction in melanoma) and Intralesional (IL) injection (for some solution vials) are also specified.
Dosing Schedule & Frequency	Doses are frequently expressed in International Units (IU) per square meter of body surface area (IU/m^2). The frequency is typically three times a week (every other day) or daily, depending on the disease, often for a period of several months (e.g., Chronic Hepatitis B: 5–10 million IU SC three times a week for 4–6 months).
Preparation Requirements	Powder for Injection must be reconstituted using the supplied Diluent for IntronA (Sterile Water for Injection USP) prior to administration. Ready-to-use solution vials do not require this step.
Age-Group Rules	Use is authorized for adults for many indications. For Chronic Hepatitis C, use is indicated in a combination regimen for children three years of age and older and adolescents.

Official Procedural Conditions

Dose Initiation and Monitoring: Treatment must be started under physician supervision. Close monitoring of laboratory values and clinical response is required.
Self-Administration: Patients may be authorized to self-administer the dose for subcutaneous maintenance dose regimens, at the discretion of the physician.
Dose Adjustment: Dosage modification or temporary discontinuation is mandated if adverse events occur, or if there is a lack of response (e.g., discontinuation for Chronic Myelogenous Leukaemia after 8–12 weeks if remission is not achieved).

This summary provides the framework for administering IntronA, defining the specific injection methods and frequency rules necessary for its use, while emphasizing the requirement for continuous physician oversight and dose adjustment based on patient tolerance and measurable efficacy.

Recent Clinical Evidence

Research Evidence / Overview of studies for IntronA

The research base for IntronA (Interferon Alfa-2b) includes evaluations from Randomized Controlled Trials (RCTs) and long-term observational studies, which focused on specific health conditions. This summary describes the landscape of that research, what was examined, and where recognized limitations or uncertainties exist.

Research Evidence for Viral Hepatitis (Chronic Hepatitis B and C)

IntronA was studied for both Chronic Hepatitis B (CHB) and Chronic Hepatitis C (CHC), conditions where research examined patient outcomes related to systemic or functional imbalance. Researchers conducted short-to-intermediate term RCTs, often comparing the treatment to either observation or combination therapy.

The research examined viral markers and measures related to liver health. For CHB, studies monitored the levels of the virus in the blood and looked for the disappearance of the Hepatitis B e-antigen (HBeAg) loss. Studies monitored these viral markers, and findings describe patterns observed in the studies where measurements were noted to shift toward undetectable levels in some patients after the study period concluded. For CHC, the primary outcome monitored was Sustained Virologic Response (SVR), meaning the virus was not detectable in the blood six months after treatment had ended. The evidence base for this regimen has been largely superseded by the development of Direct-Acting Antiviral (DAA) agents.

Research Evidence for Hematologic and Solid Tumors

IntronA was also evaluated in research involving certain cancers, including Malignant Melanoma, Hairy Cell Leukemia (HCL), and historically, Chronic Myelogenous Leukemia (CML). For HCL, observational cohorts explored outcomes related to physical discomfort. Research describes patterns where measurements consistent with the normalization of blood cell counts (hematologic response) were observed in many patients studied.

For Malignant Melanoma, large RCTs compared the treatment against observation in patients who had already had surgery. These studies monitored Relapse-Free Survival (RFS) and Overall Survival (OS). Research explored patterns observed in one large trial where RFS and OS measurements were tracked and compared for the study treatment group versus the observation group. However, analysis across different trials showed that the findings were mixed regarding the consistency of the OS measurement.

The Evolving Evidence Landscape and Research Gaps

The research evidence for IntronA has undergone significant change, especially with the introduction of newer, more targeted agents for both chronic hepatitis and certain cancers. As a result, much of the existing research is considered historical. Regulators or research reviews acknowledge that comparative evidence is lacking between IntronA and the newer treatments that have become widely used for CML and Hepatitis C.

Key Studies & References

Community register of medicinal products: IntronA Annex I (Regulatory Summary)

Frequently Asked Questions (FAQ)

Common questions about IntronA (FAQ)

Q: Does IntronA interfere with the results of blood tests or other lab work?

Regulatory documents indicate that IntronA may cause changes in various laboratory test results. These changes can include shifts in blood cell counts, liver enzyme levels, kidney function markers, and thyroid function. These potential fluctuations are typically monitored by a healthcare professional as part of treatment management.

Q: Can I store IntronA in the refrigerator door?

According to the official product information, IntronA must be stored in the refrigerator, but freezing should be avoided. It is important to follow the precise storage temperature range stated in the official instructions to help maintain the medicine’s effectiveness and quality.

Q: Is IntronA a chemotherapy drug?

IntronA is classified as an interferon, which is a type of protein that occurs naturally in the body. It works by affecting the immune system and the growth of cells. While it is used to treat some cancers, it is not categorized as a traditional cytotoxic chemotherapy drug, which directly kills cells.

Q: What should I do if I miss a scheduled dose of IntronA?

Official product information states that following the prescribed schedule is important. If a dose is missed, regulatory information advises contacting a healthcare professional promptly for specific guidance regarding the next steps. Taking a double dose to compensate for a missed one is generally not advised by official sources.

Q: Does IntronA need to be refrigerated?

Yes, regulatory documents specify that IntronA must be stored in the refrigerator between 2°C and 8°C (36°F and 46°F). Proper refrigeration helps maintain the medicine's stability and effectiveness. The product must not be frozen, as freezing can damage it.

How should IntronA be stored and disposed of?

How to Store and Dispose of IntronA?

IntronA must be stored in a refrigerator between 2 C and 8 C (36 F and 46 F). It is essential to keep it in the original carton to protect the medicine from light and to protect it from freezing. Do not use the solution if it appears discolored, cloudy, or contains particles. For multi-dose vials, the product must be discarded after one month (28–31 days) from the date of first entry, even if there is medicine remaining.

Disposal Requirements

Used syringes, needles, and other sharps must be placed immediately into an FDA-cleared, puncture-resistant sharps disposal container. This container must be sealed and disposed of according to your community's local guidelines for hazardous waste. Do not dispose of used sharps in household trash or flush them down the toilet. Keep this and all medicines out of the reach of children.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.